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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Hebrew lan-
guage. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre 
was asked to collect demographic, clinical data, and the JAMAR in 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation 
phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling 
effects, internal consistency, Cronbach’s alpha, interscale correlations, and construct validity (convergent and discriminant 
validity). A total of 116 JIA patients (17.2% systemic, 56% oligoarticular, 20.7% RF negative poly-arthritis, and 6.1% other 
categories) and 98 healthy children were enrolled in two centres. The JAMAR components discriminated well healthy 
subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Hebrew 
version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical 
practice and in clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Hebrew parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
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(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Hebrew language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from April 2011 to 
September 2013. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections.
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, and 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW); and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from the previous visit (cat-
egorical scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) sub-scales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2), and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with two–third for-
ward and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultural 
adapted in a similar language (i.e., Spanish in South Ameri-
can countries), only the probe technique was performed. 
Reading comprehension and understanding of the translated 
questionnaires were tested in a probe sample of ten JIA par-
ents and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data, and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption (mean and standard deviation [SD] equivalence); 
the second Likert assumption or equal item-scale correla-
tions (Pearson r all items within a scale should contribute 
S229Rheumatology International (2018) 38 (Suppl 1):S227–S233 
1 3
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core-set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Test–retest reliability of the Hebrew version 
of the JAMAR was not assessed.
Quantitative data were reported as medians with first and 
third quartiles and categorical data as absolute frequencies 
and percentages.
The complete Hebrew parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Hebrew JAMAR was fully cross-culturally adapted from 
the standard English version with two forward and two back-
ward translations with a concordance for 114/123 transla-
tions lines (92.7%) for the parent version and 110/120 lines 
(91.7%) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the ten parents tested 
(median = 100%; range 90–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 100–100%). 
Both versions of the JAMAR were unmodified after the 
probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 118 JIA patients and 98 healthy children (total of 
216 subjects), were enrolled at two paediatric rheumatology 
centres. Two patients did not give the consent to use their 
data.
In the remaining 116 JIA subjects, the JIA categories 
were 17.2% with systemic arthritis, 56% with oligoarthritis, 
20.7% with RF negative poly-arthritis, 0.9% with RF posi-
tive poly-arthritis, 1.7% with psoriatic arthritis, 2.6% with 
enthesitis-related arthritis, and 0.9% with undifferentiated 
arthritis (Table 1).
A total of 207/214 (96.7%) subjects had the parent ver-
sion of the JAMAR completed by a parent (110 from parents 
of JIA patients and 97 from parents of healthy children). The 
JAMAR was completed by 136/207 (65.7%) mothers and 
71/207 (34.3%) fathers. The child version of the JAMAR 
was completed by 131/214 (61.2%) children age 6.9 or older. 
In addition, patients younger than 7 years, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (first–third quartiles)] obtained for the PF, 
the PhH, the PsH sub-scales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all the JAMAR items, the median number of missing 
responses was 1.8 (0–7.3).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items, whereas a reduced number of response 
choices was used for PF items 7 and 9. The mean and SD 
of the items within a scale were roughly equivalent for the 
PF and for the HRQoL items, except for HRQoL item 1 
(data not shown). The median number of items marked as 
not applicable was 0% (0–2%) for the PF and 3% (1–8%) for 
the HRQoL.
Floor and ceiling effect
The median floor effect was 83.6% (60.9–90.9%) for the 
PF items, 55.5% (32.7–72.7%) for the HRQoL-PhH items, 
and 60.9% (50.9–75.5%) for the HRQoL-PsH items. The 
median ceiling effect was 0.9% (0–4.5%) for the PF items, 
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies and %) for the 116 JIA patients
Systemic Oligoar-
thritis
RF− poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 20 N = 65 N = 24 N = 1 N = 2 N = 3 N = 1 N = 116 N = 98
Female 12 (60%) 49 (75.4%) 16 (66.7%) 1 (100%) 2 (100%) 2 (66.7%) 1 (100%) 83 (71.6%) 60 (61.2%)
Age at visit 12.6 
(8.3–16)
9.8 (7.3–
14.2)
11 (9.5–
14.6)
17.6 (17.6–
17.6)
18.2 (16.7–
19.7)
17.2 (15.6–
18.5)
16.2 (16.2–
16.2)
11.3 
(8–15.3)*
11.5 (8.7–15)
Age at onset 6.8 (3.7–9.4) 4.4 (2.3–9.2) 6.5 (3.2-9) 14.2 (14.2–
14.2)
16.9 
(15.9–18)
15.1 (13.2–
15.1)
14.3 (14.3–
14.3)
5.5 (3–10)*
Disease 
duration
5.6 (0.7–8.4) 4.1 (1.1–6.9) 4.8 
(2.9–6.5)
3.4 
(3.4–3.4)
1.3 
(0.8–1.7)
2.4 (2.1–3.4) 1.8 (1.8–1.8) 4.1 
(1.4–6.9)
ESR 10 (6–30) 19 (11–43) 13 (5–25) 3 (3–3) – 27 (27–27) – 13 (8–30)
MD VAS 0 (0–2) 2 (0–3) 0 (0–2) – 3 (3–3) – – 0 (0–3)
No. swollen 
joints
0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0) 3.5 (3–4) 0 (0–0) 1 (1–1) 0 (0–1)*
No. joints 
with pain
0 (0–0.5) 0 (0–1) 0 (0–1.5) 0 (0–0) 3.5 (3–4) 1 (0–1) 1 (1–1) 0 (0–1)
No. joints 
with LOM
0 (0–0) 0 (0–1) 0 (0–2) 0 (0–0) 3.5 (3–4) 0 (0–2) 1 (1–1) 0 (0–1)
No. active 
joints
0 (0–0) 1 (0–1) 0 (0-0.5) 0 (0–0) 3.5 (3–4) 0 (0–1) 1 (1–1) 0 (0–1)*
Active 
systemic 
features
3 (15%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (2.6%)*
ANA status 0 (0%) 11 (16.9%) 1 (4.2%) 0 (0%) 1 (50%) 0 (0%) 0 (0%) 13 (11.2%)
Uveitis 0 (0%) 11 (16.9%) 1 (4.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 12/114 
(10.5%)
PF total 
score
0 (0–5) 2 (0-5.5) 4 (1–7) – – 2 (0–4) 6 (6–6) 2 (0–6) 0 (0–0)#
Pain VAS 0 (0–2.5) 2 (0–6) 1 (0–6) – – 3.5 (0.5–6.5) 4 (4–4) 1 (0-5.5) 0 (0–0)#
Disease 
activity 
VAS
0 (0–3) 3 (0–6.5) 1.5 (0–5.5) – – 2.5 (1–4) 7 (7–7) 2 (0–6)
Well-being 
VAS
0.8 (0–2.5) 2 (0–6) 0.5 (0–5) – – 2.8 (1.5–4) 5 (5–5) 1.5 (0–5)
HRQoL-
PhH
2 (0–5) 3 (0–6) 3 (1–8) – 5 (5–5) 5.5 (1–10) 8 (8–8) 2.5 (0–6) 0 (0–0)#
HRQoL-
PsH
2 (0–5) 1 (0–3) 1 (0–8) – 3 (3–3) 4 (1–7) 3 (3–3) 1 (0–4) 0 (0–0)#
HRQoL 
total score
5 (2–9) 4 (0–9.5) 3 (1–16) – 8 (8–8) 9.5 (2–17) 11 (11–11) 4.5 (1–10) 0 (0–0)#
Pain/swell. 
in > 1 joint
8/19 (42.1%) 41/64 
(64.1%)
14/23 
(60.9%)
– 1/1 (100%) 1/2 (50%) 1 (100%) 66/110 
(60%)
0 (0%)#
Morning 
stiffness 
> 15 min
5/19 (26.3%) 12/64 
(18.8%)
4/23 
(17.4%)
– 0 (0%) 1/2 (50%) 0 (0%) 22/110 
(20%)
0 (0%)#
Subjective 
remission
6/18 (33.3%) 34/64 
(53.1%)
12/23 
(52.2%)
– 0 (0%) 1/2 (50%) 1 (100%) 54/109 
(49.5%)
In treatment 13/19 
(68.4%)
31/62 (50%) 18/23 
(78.3%)
– 1/1 (100%) 2/2 (100%) 1 (100%) 66/108 
(61.1%)
Reporting 
side effects
5/13 (38.5%) 10/31 
(32.3%)
5/18 
(27.8%)
– 0 (0%) 0 (0%) 0 (0%) 20/66 
(30.3%)
Taking 
medication 
regularly
7/12 (58.3%) 22/31 (71%) 17/18 
(94.4%)
– 0 (0%) 2/2 (100%) 0 (0%) 48/65 
(73.8%)
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7.3% (3.6–13.6%) for the HRQoL-PhH items, and 1.8% 
(0.9–4.5%) for the HRQoL-PsH items. The median floor 
effect was 40% for the pain VAS, 30.9% for the disease activ-
ity VAS, and 34.5% for the well-being VAS. The median 
ceiling effect was 1.8% for the pain VAS, 6.4% for the dis-
ease activity VAS, and 0.9% for the well-being VAS.
Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 100% of the 
PF items and for 100% of the HRQoL items.
Item internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 100% of items 
of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.89 for PF-LL, 0.93 for PF-HW, and 
0.91 for PF-US. Cronbach’s alpha was 0.90 for HRQoL-PhH 
and 0.86 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.01 to 
0.7 (median = 0.5). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.7, 
p < 0.001). The correlation of the PF total score with the ESR 
was not significant (p = 0.89). For the HRQoL, the median 
correlation of the PhH with the JIA core set of outcome 
variables ranged from 0.3 to 0.8 (median = 0.5), whereas 
for the PsH ranged from 0.2 to 0.5 (median = 0.2). The PhH 
showed the best correlation with the parent’s assessment of 
pain (r = 0.8, p < 0.001) and the PsH with the parent global 
assessment of well-being (r = 0.5, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, 
and the disease activity VAS and the physician-centred and 
laboratory measures were 0.5 (0.3–0.6), 0.4 (0.3–0.5), and 
0.4 (0.3–0.5), respectively.
Discussion
In this study, the Hebrew version of the JAMAR was cross-
culturally adapted from the original standard English version 
with two forward and two backward translations. According 
to the results of the validation analysis, the Hebrew parent 
and patient versions of the JAMAR possess satisfactory psy-
chometric properties. The disease-specific components of 
the questionnaire discriminated well between patients with 
JIA and healthy controls. Psychometric performances were 
Data related to the JAMAR refer to the 110 JIA patients and to the 97 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy
*p < 0.05, **p < 0.001, #p < 0.0001
Table 1  (continued)
Systemic Oligoar-
thritis
RF− poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 20 N = 65 N = 24 N = 1 N = 2 N = 3 N = 1 N = 116 N = 98
With 
problems 
attending 
school
3/14 (21.4%) 7/29 (24.1%) 6/18 
(33.3%)
– 1/1 (100%) 1/1 (100%) 0 (0%) 18/64 
(28.1%)
0 (0%)#
Satisfied 
with 
disease 
outcome
16/19 
(84.2%)
39/63 
(61.9%)
16/23 
(69.6%)
– 0 (0%) 1/2 (50%) 0 (0%) 72/109 
(66.1%)
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good for all domains of the JAMAR and the overall internal 
consistency was excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core-set 
parameters ranged from weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
Test–retest reliability was not assessed in this patient sam-
ple. The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care.
In conclusion, the Hebrew version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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